What is Aura Biosciences, Inc.'s stock issuance proceeds?

Aura Biosciences, Inc. (AURA) reported stock issuance proceeds of $56K in Q1 2026.

What is the long-term trend for Aura Biosciences, Inc.'s stock issuance proceeds?

Over 3 years (2021 to 2024), Aura Biosciences, Inc.'s stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $78.7M to $0.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Aura Biosciences, Inc. AURA Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Merck & Co.MRK

$157M+726%

ImmunityBio, Inc.IBRX

$971K+341%

UroGen PharmaURGN

$0-100%

IDEAYA Biosciences, Inc.IDYA

$1.19M+4.9%

CG OncologyCGON

$391.55M+57,312%

Relmada Therapeutics, Inc.RLMD

$160M+583%

Other financials

Income statement

See full

Operating income-$34.9M-20.1%

Net income-$33.7M-22.6%

EPS (diluted)-$0.50+9.1%

Balance sheet

See full

Cash & equivalents$84.8M+122%

Total debt$17.0M-7.9%

Total equity$107.2M-16.2%

Total assets$137.7M-11.4%

Cash flow

See full

Operating cash flow-$29.9M-28.0%

CapEx$102.0K-45.5%

Free cash flow-$30.0M-27.4%

Valuation

See full

Market cap$709.23M+89.4%

Enterprise value$641.43M+80.8%

Returns & leverage

See full

Return on equity-95.6%+222pp

Debt / equity0.2×0.0×

Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aura Biosciences, Inc.'s stock issuance proceeds?: Aura Biosciences, Inc. (AURA) reported stock issuance proceeds of $56K in Q1 2026.
What is the long-term trend for Aura Biosciences, Inc.'s stock issuance proceeds?: Over 3 years (2021 to 2024), Aura Biosciences, Inc.'s stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $78.7M to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.